These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 15213599)
1. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus. Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599 [TBL] [Abstract][Full Text] [Related]
2. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. Kimura F; Watanabe J; Hata H; Fujisawa T; Kamata Y; Nishimura Y; Jobo T; Kuramoto H J Cancer Res Clin Oncol; 2004 Mar; 130(3):161-8. PubMed ID: 14689303 [TBL] [Abstract][Full Text] [Related]
3. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression. Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899 [TBL] [Abstract][Full Text] [Related]
4. Cyclin D1 expression in endometrioid-type endometrial adenocarcinoma is correlated with histological grade and proliferative activity, but not with prognosis. Nishimura Y; Watanabe J; Jobo T; Kato N; Fujisawa T; Kamata Y; Kuramoto H Anticancer Res; 2004; 24(4):2185-91. PubMed ID: 15330159 [TBL] [Abstract][Full Text] [Related]
5. Cellular retinol binding protein-1 expression in endometrial hyperplasia and carcinoma: diagnostic and possible therapeutic implications. Orlandi A; Ferlosio A; Ciucci A; Francesconi A; Lifschitz-Mercer B; Gabbiani G; Spagnoli LG; Czernobilsky B Mod Pathol; 2006 Jun; 19(6):797-803. PubMed ID: 16575402 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. Kato N; Watanabe J; Jobo T; Nishimura Y; Fujisawa T; Kamata Y; Kuramoto H J Cancer Res Clin Oncol; 2003 Apr; 129(4):222-6. PubMed ID: 12684894 [TBL] [Abstract][Full Text] [Related]
7. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA. Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717 [TBL] [Abstract][Full Text] [Related]
8. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Lax SF; Pizer ES; Ronnett BM; Kurman RJ Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673 [TBL] [Abstract][Full Text] [Related]
9. High expression of skp2 correlates with poor prognosis in endometrial endometrioid adenocarcinoma. Kamata Y; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Hattori M; Obokata A; Kuramoto H J Cancer Res Clin Oncol; 2005 Sep; 131(9):591-6. PubMed ID: 16080017 [TBL] [Abstract][Full Text] [Related]
10. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Ambros RA; Vigna PA; Figge J; Kallakury BV; Mastrangelo A; Eastman AY; Malfetano J; Figge HL; Ross JS Cancer; 1994 Mar; 73(6):1686-92. PubMed ID: 8156496 [TBL] [Abstract][Full Text] [Related]
11. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas. Feng YZ; Shiozawa T; Horiuchi A; Shih HC; Miyamoto T; Kashima H; Suzuki A; Nikaido T; Konishi I Virchows Arch; 2005 Nov; 447(5):816-22. PubMed ID: 16021509 [TBL] [Abstract][Full Text] [Related]
12. Different trends of p53, MDM2 and p14 ARF expression patterns in endometrial adenocarcinomas versus hyperplasia. Buchynska LG; Nesina IP; Kashuba EV Exp Oncol; 2007 Dec; 29(4):287-94. PubMed ID: 18199985 [TBL] [Abstract][Full Text] [Related]
13. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Kashima H; Wu RC; Wang Y; Sinno AK; Miyamoto T; Shiozawa T; Wang TL; Fader AN; Shih IeM Gynecol Oncol; 2015 Nov; 139(2):338-44. PubMed ID: 26343160 [TBL] [Abstract][Full Text] [Related]
14. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241 [TBL] [Abstract][Full Text] [Related]
15. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Sivridis E; Giatromanolaki A; Koukourakis MI; Georgiou L; Anastasiadis P Histopathology; 2002 Jan; 40(1):92-100. PubMed ID: 11903603 [TBL] [Abstract][Full Text] [Related]
16. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Cao QJ; Einstein MH; Anderson PS; Runowicz CD; Balan R; Jones JG Int J Gynecol Pathol; 2002 Apr; 21(2):147-54. PubMed ID: 11917224 [TBL] [Abstract][Full Text] [Related]
17. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of cyclin A with reference to p53 expression in endometrial endometrioid carcinomas. Shiozawa T; Xin L; Nikaido T; Fujii S Int J Gynecol Pathol; 1997 Oct; 16(4):348-53. PubMed ID: 9421074 [TBL] [Abstract][Full Text] [Related]
19. Immunolocalization of ERK1/2 and p-AKT in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group. Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996 [TBL] [Abstract][Full Text] [Related]
20. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Watanabe J; Sato H; Kanai T; Kamata Y; Jobo T; Hata H; Fujisawa T; Ohno E; Kameya T; Kuramoto H Br J Cancer; 2002 Jul; 87(1):81-5. PubMed ID: 12085261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]